In a report examining BeOne Medicines’ beat-and-raise quarter and the next phase of its growth, the analysis argues that broad-based Brukinsa momentum and a widening portfolio reinforce the durability of the company’s commercial growth profile. BeOne Medicines (ONC/688235.SS) delivered 3Q26 product sales of US$1.86bn, up 33% y/y, ahead of the report’s US$1.74bn estimate, with Brukinsa contributing US$1.39bn (+34% y/y) against an expected US$1.31bn.
Continue Reading
This article is for pass holders.
30-Day Pass$12.00One-time purchase · no auto-renewalBuy 30 DaysSave $24.00
365-Day Pass$120.00
Already a pass holder? Sign in · Continue with Google